Early stages of clear cell (glycogen rich cell) invasive ductal carcinoma (IDC) of the breast: Good or bad prognosis?

Nacul, Mario Javier; Gerardi, C. Garcia; Japaze, H; Deza, Ernesto Gil; Gercovich, N.; Díaz, C; Russo, Monica Lo; Rolnik, Benjamin; Tognelli, Flavio; Morgenfeld, Eduardo L.; Rivarola, Edgardo G. J.; Gercovich, Felipe G.

doi:10.1200/jco.2011.29.15_suppl.e11053

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest to date study, based on the analysis from the Surveillance, Epidemiology and End Results (SEER) database, identified 155 cases of GRCC among the 1,251,584 cases of other (non-GRCC) breast carcinomas (frequency ∼0.01%). 5 A study of Toikkanen and Joensuu 6 revealed 6 cases of GRCC among the 439 cases of IBCs (∼1.4%); a similar incidence (1.8%) was reported by Nacul et al, 7 whereas Kuroda et al 8 reported 20 cases of GRCC among the 723 consecutive patients with primary breast carcinomas (∼2.8%). Our own experience also indicates a very low incidence of GRCC (∼0.2%).…”

Section: Epidemiology Of Grccmentioning

confidence: 57%

Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review

Vranić

Skenderi²,

Beslagic

et al. 2020

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Glycogen-rich clear cell carcinoma (GRCC) is a very rare form of primary breast cancer (< 0.1% of all breast cancers). It is characterized by the presence of neoplastic cells with a glycogen-abundant clear cytoplasm (the Periodic Acid Schiffpositive, diastase-sensitive). The expression of steroid receptors (estrogen and progesterone receptors) has been variably reported (35% to 100% of the cases), whereas most studies reported low human epidermal growth factor receptor 2 positivity in GRCC. High androgen receptor positivity without androgen receptor splice variant-7 was reported in one recent study. Although sparse, the preliminary theranostic data on GRCC indicate the potential of targeted treatments in selected cases (antiandrogen, PIK3CA, and immune checkpoint inhibitors). Because of its rarity, the prognosis for GRCC patients remains controversial. Herein, we comprehensively appraise the epidemiological, morphologic, molecular, and clinical characteristics of this rare mammary malignancy.

show abstract

Section: Epidemiology Of Grccmentioning

confidence: 57%